Blueprint Medicines Corp
BPMC129.460USD
+0.180+0.14%
Close 07/30, 16:00（ET）Quotes delayed by 15 min
8.36BMarket Cap
LossP/E TTM
More Details of Blueprint Medicines Corp Company
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Company Info
Ticker SymbolBPMC
Company nameBlueprint Medicines Corp
IPO dateApr 30, 2015
Founded at2008
CEOMs. Kathryn D (Kate) Haviland
Number of employees649
Security typeOrdinary Share
Fiscal year-endApr 30
Address45 Sidney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02139
Phone16173747580
Websitehttps://www.blueprintmedicines.com/
Ticker SymbolBPMC
IPO dateApr 30, 2015
Founded at2008
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024Q3
FY2024Q2
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Shareholding Stats
Updated: Wed, Jul 30
Updated: Wed, Jul 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.25%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.57%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Other
63.20%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.25%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.57%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Other
63.20%
Shareholder Types
Shareholders
Proportion
Investment Advisor
55.07%
Investment Advisor/Hedge Fund
39.84%
Hedge Fund
8.90%
Research Firm
2.98%
Sovereign Wealth Fund
1.10%
Individual Investor
0.93%
Venture Capital
0.77%
Pension Fund
0.56%
Bank and Trust
0.48%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
686
71.41M
110.43%
-1.17M
2025Q1
702
71.75M
110.98%
-1.27M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
6.63M
10.25%
-134.36K
-1.99%
Mar 31, 2025
T. Rowe Price Associates, Inc.
5.35M
8.28%
-266.46K
-4.74%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.89M
7.57%
-106.17K
-2.12%
Mar 31, 2025
Avoro Capital Advisors LLC
3.85M
5.95%
+2.67M
+224.89%
Mar 31, 2025
Wellington Management Company, LLP
3.07M
4.75%
-1.21M
-28.22%
Mar 31, 2025
State Street Global Advisors (US)
2.68M
4.15%
+183.91K
+7.36%
Mar 31, 2025
JP Morgan Asset Management
2.03M
3.15%
+1.33M
+187.97%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.52M
2.35%
+32.55K
+2.18%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
1.30M
2.01%
+605.78K
+86.91%
Mar 31, 2025
Macquarie Investment Management
1.29M
1.99%
+27.92K
+2.22%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Invesco Biotechnology & Genome ETF
3.22%
Tema Oncology ETF
2.73%
SPDR S&P Biotech ETF
2.04%
Motley Fool Small-Cap Growth ETF
1.6%
Direxion Daily S&P Biotech Bull 3X Shares
1.47%
American Century Focused Dynamic Growth ETF
1.32%
JPMorgan Fundamental Data Science Small Core ETF
1.1%
ProShares Ultra Nasdaq Biotechnology
0.94%
Hypatia Women CEO ETF
0.8%
Invesco Nasdaq Biotechnology ETF
0.73%
View more
Invesco Biotechnology & Genome ETF
Proportion3.22%
Tema Oncology ETF
Proportion2.73%
SPDR S&P Biotech ETF
Proportion2.04%
Motley Fool Small-Cap Growth ETF
Proportion1.6%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.47%
American Century Focused Dynamic Growth ETF
Proportion1.32%
JPMorgan Fundamental Data Science Small Core ETF
Proportion1.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.94%
Hypatia Women CEO ETF
Proportion0.8%
Invesco Nasdaq Biotechnology ETF
Proportion0.73%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
